Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 329Cisplatin 276Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 210Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Toll-Like Receptor 1 × Clear all
NCT03083873 2023-10-12

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Iovance Biotherapeutics, Inc.

Phase 2 Completed
64 enrolled 15 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡